Perceptive Advisors LLC decreased its position in shares of Versartis Inc (NASDAQ:VSAR) by 21.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,488,160 shares of the biopharmaceutical company’s stock after selling 400,000 shares during the period. Perceptive Advisors LLC owned about 4.16% of Versartis worth $3,273,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in VSAR. Ascend Capital LLC raised its holdings in shares of Versartis by 18.5% in the 4th quarter. Ascend Capital LLC now owns 623,614 shares of the biopharmaceutical company’s stock worth $1,371,000 after purchasing an additional 97,184 shares in the last quarter. Vanguard Group Inc. increased its stake in Versartis by 11.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock valued at $19,569,000 after buying an additional 118,894 shares during the period. Jane Street Group LLC acquired a new position in Versartis in the 3rd quarter valued at approximately $319,000. Artal Group S.A. increased its stake in Versartis by 14.3% in the 3rd quarter. Artal Group S.A. now owns 400,000 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 50,000 shares during the period. Finally, Virtu Financial LLC grew its position in Versartis by 713.6% in the fourth quarter. Virtu Financial LLC now owns 163,585 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 143,478 shares in the last quarter. 48.52% of the stock is owned by institutional investors.
Shares of Versartis Inc (NASDAQ VSAR) traded down $0.03 during midday trading on Tuesday, hitting $1.70. 113,909 shares of the stock traded hands, compared to its average volume of 561,220. Versartis Inc has a one year low of $1.55 and a one year high of $22.30. The company has a market cap of $64.46, a price-to-earnings ratio of -0.72 and a beta of 2.21. The company has a quick ratio of 14.62, a current ratio of 14.61 and a debt-to-equity ratio of 0.07.
In other news, insider Jay Shepard sold 14,446 shares of Versartis stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $1.80, for a total value of $26,002.80. Following the sale, the insider now directly owns 602,298 shares in the company, valued at $1,084,136.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 21,400 shares of company stock worth $38,520 over the last quarter. 10.90% of the stock is owned by corporate insiders.
Several research firms have commented on VSAR. Canaccord Genuity downgraded shares of Versartis from a “buy” rating to a “hold” rating and decreased their target price for the stock from $9.00 to $5.00 in a research report on Friday, March 2nd. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $5.13.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.